| Sara Douglas, NP | |
|
901 Medical Center Dr, Ste 203, Dayton, NV 89403-7459 | |
| (775) 445-7630 | |
| Not Available |
| Full Name | Sara Douglas |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 9 Years |
| Location | 901 Medical Center Dr, Dayton, Nevada |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295190304 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | APRN002052 (Nevada) | Primary |
| 363LF0000X | Nurse Practitioner - Family | 225858 (Arizona) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Healthy Living At Home -carson City, Llc | Carson city, NV | Home health agency |
| Kindred At Home | Galena, NV | Home health agency |
| Carson Tahoe Regional Medical Center | Carson city, NV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carson Tahoe Physician Clinics | 1153479027 | 83 |
News Archive
Shire Canada Inc., a division of Shire plc, the global specialty biopharmaceutical company, is proud to announce that MEZAVANT® (mesalamine delayed and extended release tablets), the first and only once-daily mesalamine indicated for the induction of clinical and endoscopic remission in patients with mild-to-moderate, active ulcerative colitis (UC), has received an expanded indication to include maintenance of clinical and endoscopic remission (mucosal healing) in patients with ulcerative colitis.
The death of insulin-producing beta cells in the pancreas is a core defect in diabetes. Scientists in Italy and Texas now have discovered a new way that these cells die - by toxic imbalance of a molecule secreted by other pancreatic cells.
Breast cancer may be harder to detect and exclude among women with certain personal and lifestyle characteristics, according to research published in this week's BMJ.
Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of the second and third of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen's research and developed by Roche.
› Verified 8 days ago
| Entity Name | Carson Tahoe Physician Clinics |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023265717 PECOS PAC ID: 1153479027 Enrollment ID: O20090502000046 |
News Archive
Shire Canada Inc., a division of Shire plc, the global specialty biopharmaceutical company, is proud to announce that MEZAVANT® (mesalamine delayed and extended release tablets), the first and only once-daily mesalamine indicated for the induction of clinical and endoscopic remission in patients with mild-to-moderate, active ulcerative colitis (UC), has received an expanded indication to include maintenance of clinical and endoscopic remission (mucosal healing) in patients with ulcerative colitis.
The death of insulin-producing beta cells in the pancreas is a core defect in diabetes. Scientists in Italy and Texas now have discovered a new way that these cells die - by toxic imbalance of a molecule secreted by other pancreatic cells.
Breast cancer may be harder to detect and exclude among women with certain personal and lifestyle characteristics, according to research published in this week's BMJ.
Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of the second and third of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen's research and developed by Roche.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sara Douglas, NP Po Box 2168, Carson City, NV 89702-2168 Ph: (775) 445-8790 | Sara Douglas, NP 901 Medical Center Dr, Ste 203, Dayton, NV 89403-7459 Ph: (775) 445-7630 |
News Archive
Shire Canada Inc., a division of Shire plc, the global specialty biopharmaceutical company, is proud to announce that MEZAVANT® (mesalamine delayed and extended release tablets), the first and only once-daily mesalamine indicated for the induction of clinical and endoscopic remission in patients with mild-to-moderate, active ulcerative colitis (UC), has received an expanded indication to include maintenance of clinical and endoscopic remission (mucosal healing) in patients with ulcerative colitis.
The death of insulin-producing beta cells in the pancreas is a core defect in diabetes. Scientists in Italy and Texas now have discovered a new way that these cells die - by toxic imbalance of a molecule secreted by other pancreatic cells.
Breast cancer may be harder to detect and exclude among women with certain personal and lifestyle characteristics, according to research published in this week's BMJ.
Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of the second and third of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen's research and developed by Roche.
› Verified 8 days ago